½ÃÀ庸°í¼­
»óǰÄÚµå
1406024

´ëÀå³»½Ã°æ °Ë»ç ±â±â : ½ÃÀå Á¡À¯À² ºÐ¼®, »ê¾÷ µ¿Çâ°ú Åë°è, ¼ºÀå ¿¹Ãø(2024-2029³â)

Colonoscopy Devices - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts 2024 - 2029

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: Mordor Intelligence | ÆäÀÌÁö Á¤º¸: ¿µ¹® | ¹è¼Û¾È³» : 2-3ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡á º¸°í¼­¿¡ µû¶ó ÃֽŠÁ¤º¸·Î ¾÷µ¥ÀÌÆ®ÇÏ¿© º¸³»µå¸³´Ï´Ù. ¹è¼ÛÀÏÁ¤Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

¼¼°èÀÇ ´ëÀå³»½Ã°æ °Ë»ç ±â±â ½ÃÀåÀº 2024³â¿¡ 22¾ï 4,000¸¸ ´Þ·¯·Î Æò°¡µÇ°í, ¿¹Ãø ±â°£(2024-2029³â) CAGRÀº 5.20%·Î 2029³â¿¡´Â 28¾ï 8,000¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµÇ°í ÀÖ½À´Ï´Ù.

´ëÀå³»½Ã°æ ±â±â - ½ÃÀå - IMG1

ÆÒµ¥¹ÍÀº Ãʱ⿡ ½ÃÀå¿¡ ºÎÁ¤ÀûÀÎ ¿µÇâÀ» ¹ÌÃÆ½À´Ï´Ù. COVID-19·Î ÀÎÇÑ ´ëÀå¾Ï Ä¡·á Áß´Ü ¹× Áö¿¬Àº Ãʱ⿡´Â ½ÃÀå¿¡ ´Ù¼Ò ºÎÁ¤ÀûÀÎ ¿µÇâÀ» ¹ÌÃÆ½À´Ï´Ù. ¿¹¸¦ µé¾î ij³ª´Ù º¸°ÇºÎ°¡ 2021³â 6¿ù¿¡ ¹ßÇ¥ÇÑ ³í¹®¿¡ µû¸£¸é ij³ª´Ù¿¡¼­´Â ÆÒµ¥¹Í ´ëÀÀ Ãʱ⠴ܰ迡¼­ ´Ù¸¥ ÀÇ·á ¼­ºñ½º¿Í ÇÔ²² ´ëÀå¾Ï °ËÁøÀÌ ÀϽÃÀûÀ¸·Î ÁߴܵǾú½À´Ï´Ù. ÀÌ Áß´ÜÀº ÀÇ·á ±â°üÀÌ COVID-19 ¹ßº´À» ¿¹¹æÇϱâ À§ÇØ ÀûÀýÇÑ °¨¿° °ü¸® Á¶Ä¡¸¦ ¼ö¸³Çϰí COVID-19 ȯÀÚ¸¦ À§ÇÑ ÀÇ·á ½Ã½ºÅÛÀÇ ¿ª·®À» È®º¸Çϱâ À§ÇØ ÇÊ¿äÇß½À´Ï´Ù. ±×·¯³ª ÆÒµ¥¹Í ÈĹݱ⿡ Á¢¾îµé¸é¼­ ¾Ï °ËÁø°ú °ü·ÃµÈ ¿©·¯ °¡Áö ÀÎ½Ä Á¦°í ÇÁ·Î±×·¥ÀÌ ½ÃÇàµÇ°í °ËÁø ¼­ºñ½º°¡ Àç°³µÇ¸é¼­ ½ÃÀåÀº Á¡Â÷ °ßÀηÂÀ» °®±â ½ÃÀÛÇß½À´Ï´Ù. ¿¹¸¦ µé¾î 2021³â 4¿ù Community Oncology Alliance(COA)¿Í Cancer Care°¡ Çù·ÂÇÏ¿© "Time to Screen"À̶ó´Â »õ·Î¿î ÀÎ½Ä °³¼± Ä·ÆäÀÎÀ» ½ÃÀÛÇÑ °ÍÀº ÁÖ¸ñÇÒ ¸¸ÇÑ »ç·ÊÀÔ´Ï´Ù. ÀÌ Ä·ÆäÀÎÀº ´Ù¾çÇÑ À¯ÇüÀÇ ¾Ï °ËÁø¿¡ ´ëÇÑ ±³À°Àû Á¤º¸¸¦ °ø°³Çϰí, °ËÁø ¿¹¾àÀ» Áö¿øÇÔÀ¸·Î½á ¾Ï °ËÁø¿¡ ´ëÇÑ °ü½ÉÀ» ³ôÀÌ´Â °ÍÀ» ¸ñÇ¥·Î Çß½À´Ï´Ù. ÀÌ·Î ÀÎÇØ Ãʱ⿡´Â ½ÃÀåÀÌ ºÒ¸®ÇÑ ¿µÇâÀ» ¹Þ¾ÒÁö¸¸, ¾Ï Ä¡·á°¡ Àç°³µÇ¸é¼­ ½ÃÀåÀÌ °ßÀηÂÀ» °®±â ½ÃÀÛÇß°í, ¿¹Ãø ±â°£ Áß »ó½Â¼¼¸¦ À¯ÁöÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

´ëÀå³»½Ã°æ °Ë»ç ±â±â ½ÃÀåÀº Àúħ½ÀÀû ±â¼ú¿¡ ´ëÇÑ ¼±È£µµ Áõ°¡, ±â¼ú ¹ßÀü, ´ëÀå¾Ï À¯º´·ü Áõ°¡¿¡ ÀÇÇØ ÁÖµµµÇ°í ÀÖ½À´Ï´Ù. ´ëÀå¾ÏÀÇ ¿øÀÎÀº ¾ÆÁ÷ ¹àÇôÁöÁö ¾Ê¾Ò½À´Ï´Ù. ¶ÇÇÑ ÀϺΠÀ¯ÀüÀû ¹× ȯ°æÀû ¿äÀÎÀÌ ¹ßº´ À§ÇèÀ» Áõ°¡½Ãų ¼ö ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î ¹Ì±¹¾ÏÇùȸ°¡ 2023³â 3¿ù¿¡ ¹ßÇ¥ÇÑ ¿¬±¸ ³í¹®¿¡ µû¸£¸é 2023³â¿¡´Â ¾à 1,53,020¸íÀÌ ´ëÀå¾Ï Áø´ÜÀ» ¹ÞÀ» °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¹Ì±¹¿¡¼­´Â 2023³â¿¡ ¾à 52,550¸íÀÌ ´ëÀå¾ÏÀ¸·Î »ç¸ÁÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¶ÇÇÑ °°Àº ÀÚ·á¿¡ µû¸£¸é 2023³â ¹Ì±¹¿¡¼­ ¾à 106,970°ÇÀÇ °áÀå¾Ï°ú 46,050°ÇÀÇ Á÷Àå¾ÏÀÌ »õ·Î ¹ß»ýÇÒ °ÍÀ¸·Î ¿¹»óµÈ´Ù°í ÇÕ´Ï´Ù. ¶ÇÇÑ À¯¸ÁÇÑ ÆÄÀÌÇÁ¶óÀÎ Èĺ¸¹°ÁúÀÇ Ãâ½Ã, ´õ ¸¹Àº ÃÖÀü¼± Ä¡·á¹ýÀÇ ÃâÇö, À¯¸®ÇÑ Á¤ºÎ ±¸»ó µîÀÇ ¿äÀÎÀÌ ½ÃÀå È®´ë¸¦ ÃËÁøÇÒ °ÍÀ¸·Î º¸ÀÔ´Ï´Ù.

¶ÇÇÑ Á¶»ç ´ë»ó ½ÃÀå¿¡¼­ ´Ù¾çÇÑ Àü·«À» äÅÃÇÏ´Â °Íµµ ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¿¹¸¦ µé¾î 2022³â 7¿ù, ÃÖ°í ¼öÁØÀÇ À§Àå(GI) Ŭ¸®´Ð ³×Æ®¿öÅ©ÀÎ ¹Ì±¹ ¼ÒÈ­±â °Ç°­("USDH")Àº ±¹³» ÃÖ´ë ±Ô¸ðÀÇ GI Genius Áö´ÉÇü ³»½Ã°æ ¸ðµâÀ» ¼³Ä¡ÇÏ¿© ȯÀÚ¿¡°Ô AI Áö¿ø ´ëÀå ³»½Ã°æ °Ë»ç¸¦ Á¦°øÇÑ´Ù°í ¹ßÇ¥Çß½À´Ï´Ù. ´ëÀå³»½Ã°æ °Ë»ç´Â ±Ã±ØÀûÀ¸·Î ´ëÀå¾ÏÀ¸·Î À̾îÁú ¼ö ÀÖ´Â ¿ëÁ¾À» ¹ß°ßÇϱâ À§ÇÑ Ç¥ÁØ °Ë»ç·Î ¿À·§µ¿¾È ¿©°ÜÁ® ¿Ô½À´Ï´Ù. ÇöÀç USDHÀÇ È¯ÀÚµéÀº Àǻ簡 Æú¸³À» ¹ß°ßÇÏ´Â µ¥ µµ¿òÀÌ µÇ´Â AI¸¦ äÅÃÇÑ ½ÄǰÀǾ౹(FDA) ½ÂÀÎ ±â±âÀÎ GI GeniusÀÇ AI Áö¿ø ½ºÅ©¸®´× ¿É¼ÇÀÇ °­Á¡À» ´©¸± ¼ö ÀÖ°Ô µÇ¾ú½À´Ï´Ù. ¶ÇÇÑ 2022³â 8¿ù, Àεµ ¸ÞµåÆ®·Î´Ð(India Medtronic Pvt Limited)Àº Àεµ¿¡¼­ GI Genius Áö´ÉÇü ³»½Ã°æ ¸ðµâÀ» Ãâ½ÃÇßÀ¸¸ç, GI Genius ¸ðµâÀº °í±Þ AI ¼ÒÇÁÆ®¿þ¾î¸¦ »ç¿ëÇÏ¿© ´Ù¾çÇÑ Å©±â, ¸ð¾ç ¹× ÇüÅÂÀÇ Àǽɽº·¯¿î Æú¸³À» ½Ç½Ã°£ ½Ã°¢Àû ¸¶Ä¿·Î °­Á¶ Ç¥½ÃÇÕ´Ï´Ù. ½Ã°¢Àû ¸¶Ä¿·Î °­Á¶ Ç¥½ÃÇÕ´Ï´Ù. º´º¯ ¹Î°¨µµ 99.7%, À§¾ç¼º 1% ¹Ì¸¸À¸·Î ¼ÒÈ­±â³»°ú Àǻ翡°Ô Ç×»ó ¼¼½ÉÇÑ Á¦2ÀÇ °üÂûÀڷμ­ÀÇ ¿ªÇÒÀ» ¼öÇàÇÕ´Ï´Ù. µû¶ó¼­ Á¦Ç° Ãâ½Ã¿Í ±â¼ú ¹ßÀüÀº ¿¹Ãø ±â°£ Áß ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

±×·¯³ª Á÷Àå Áúȯ¿¡ ´ëÇÑ ´ëü Ä¡·á¹ýÀÇ °¡¿ë¼º°ú ´ëÀå ³»½Ã°æ ½Ã¼ú¿¡ µû¸¥ À§ÇèÀº ¿¹Ãø ±â°£ Áß ½ÃÀå ¼ºÀåÀ» ÀúÇØÇÒ ¼ö ÀÖ½À´Ï´Ù.

´ëÀå³»½Ã°æ °Ë»ç ±â±â ½ÃÀå µ¿Çâ

´ëÀå³»½Ã°æ ºÎ¹®Àº ¿¹Ãø ±â°£ Áß »ó´çÇÑ ¼ºÀå¼¼¸¦ º¸ÀÏ °ÍÀ¸·Î ¿¹»ó

´ëÀå³»½Ã°æ °Ë»ç ±â±â´Â °ü°­ÀÇ ¿ªÇàÀû ½Ã¾ß¸¦ Á¦°øÇϰųª Àå ÁÖ¸§À» Àâ¾Æ´ç±æ ¶§ Àå ÁÖ¸§À» Á÷¼±È­ÇÏ¿© ´ëÀå ÁÖ¸§ÀÇ ±ÙÀ§ºÎ Ãø¸é º´º¯À» °¨ÁöÇÕ´Ï´Ù. ÀÌ´Â °Ë»ç °á°ú¿Í °ü·ÃµÈ ǰÁú ÁöÇ¥ ¹× ±âŸ ÁöÇ¥¸¦ °³¼±ÇÕ´Ï´Ù. Á¤È®µµ Çâ»ó, Á¤È®¼º, Ä¡·á ¾ÈÀü¼º µî ´Ù¸¥ Ä¡·á¹ý¿¡ ºñÇØ ´ëÀå ³»½Ã°æ °Ë»çÀÇ ÀåÁ¡Àº ¼ö¼ú¼¾ÅÍ¿¡¼­ ¼ö¿ä¸¦ Áõ°¡½Ãų °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

´ëÀå¾Ï Áõ°¡µµ ¿¹Ãø ±â°£ Áß ´ëÀå ³»½Ã°æ °Ë»ç¿¡ ´ëÇÑ ¼ö¿ä¸¦ Áõ°¡½Ãų °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¿¹¸¦ µé¾î 2021³â 7¿ù¿¡ ¹ßÇ¥µÈ NCBIÀÇ Á¶»ç¿¡ µû¸£¸é Àü ¼¼°è¿¡¼­ 525¸¸ ¸í ÀÌ»óÀÌ ´ëÀå¾ÏÀ» ¾Î°í ÀÖÀ¸¸ç, 2040³â¿¡´Â Àü ¼¼°è ½Å±Ô ´ëÀå¾Ï ȯÀÚ ¼ö°¡ 320¸¸ ¸í¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµÇ°í ÀÖ½À´Ï´Ù. µû¶ó¼­ ÀÌ·¯ÇÑ »ç·Ê·Î ÀÎÇØ ¿¬°£ ´ëÀå ³»½Ã°æ °Ë»çµµ ¼ºÀåÇÒ °¡´É¼ºÀÌ ³ôÀ¸¸ç, ÀÌ´Â ºÎ¹®ÀÇ ¼ºÀåÀ» °¡¼ÓÇÒ °ÍÀÔ´Ï´Ù. ¶ÇÇÑ ¿©·¯ ±â¾÷ÀÌ ½ÃÀå¿¡¼­ÀÇ ÀÔÁö¸¦ °­È­Çϱâ À§ÇØ ´Ù¾çÇÑ Àü·«À» äÅÃÇϰí ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î ÈÄÁöÇʸ§Àº 2021³â 4¿ù¿¡ ´ëÀå³»½Ã°æ G-EYE 700 ½Ã¸®Á Ãâ½ÃÇߴµ¥, G-EYE´Â ½º¸¶Æ® ¸ÞµðÄÃÀÌ °³¹ßÇÑ ±â¼ú·Î ÀÏ»óÀûÀÎ °Ë»ç½Ã ½Ã°¢È­, ¾ÈÁ¤È­ ¹× Á¦¾î¸¦ Áö¿øÇÕ´Ï´Ù.

¶ÇÇÑ 2021³â 11¿ù, ÄÚ½º¸ðÆÄ¸¶½´Æ¼Äýº(Cosmo Pharmaceuticals N.V.)´Â ÀΰøÁö´É(A.I.) ±â±â G.I. Genius¸¦ ´ëÀå³»½Ã°æ °Ë»ç¿Í °áÇÕÇÏ¿© ´ëÀå ¿ëÁ¾ ¹ß°ßÀ» º¸Á¶ÇÏ´Â ÀΰøÁö´É(A.I.) ±â±âÀÇ ¾ÈÀü¼º°ú À¯È¿¼ºÀ» Æò°¡ÇÑ ¹«ÀÛÀ§ ±¹Á¦ ´Ù±â°ü ÀÓ»ó½ÃÇèÀÇ ÁÖ¿ä °á°ú¸¦ ¹ßÇ¥Çß½À´Ï´Ù. ¹ßÇ¥Çß½À´Ï´Ù. ÀÌ ¿¬±¸´Â ÀÓ»ó ÇöÀå¿¡¼­ÀÇ ±¤¹üÀ§ÇÑ ±â±â »ç¿ë °æÇèÀ» Á¦°øÇϸç, G.I. Genius°¡ ¹é»ö±¤ ´ëÀå³»½Ã°æ¿¡¼­ ¹ß°ßµÇÁö ¾Ê´Â ¼±Á¾°ú ¿ëÁ¾ÀÇ ºñÀ²À» °¨¼Ò½ÃŰ´Â µ¥ ¾ó¸¶³ª È¿°úÀûÀÎÁö º¸¿©ÁÖ¾ú½À´Ï´Ù. ¶ÇÇÑ °¢ ¾÷üµéÀº ±âÁ¸ Á¦Ç° ¶óÀο¡ ÷´Ü ±â¼úÀ» µµÀÔÇϱâ À§ÇÑ ³ë·ÂÀ» ±â¿ïÀ̰í ÀÖÀ¸¸ç, ÀÌ´Â ÀÌ ºÎ¹®ÀÇ ¼ºÀåÀ» °¡¼ÓÇÒ ¼ö ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î 2022³â 12¿ù Bharti Airtel°ú Apollo Hospitals´Â Àεµ ÃÖÃÊÀÇ ÀΰøÁö´É(A.I.) Á¦¾î 5G ´ëÀå³»½Ã°æ °Ë»ç¸¦ ½Ç½ÃÇß´Ù°í ¹ßÇ¥Çß½À´Ï´Ù. ÀÌ ½ÃÇè¿¡¼­ ¿¡¾îÅÚÀÇ 5G ±â¼úÀº A.I. ¿ëµµÀ» ÅëÇØ º¸´Ù ºü¸£°í Á¤È®ÇÏ°Ô ´ëÀå¾ÏÀ» °¨ÁöÇÏ´Â µ¥ »ç¿ëµÇ¾ú½À´Ï´Ù. ÀÌ ±â¼úÀº ÃÊÀúÁö¿¬°ú ³ôÀº ó¸® ´É·ÂÀ» °¡Áö°í ÀÖ½À´Ï´Ù. ÀÌó·³ ´ëÀå¾Ï ºÎ´ã Áõ°¡, Á¦Ç° Ãâ½Ã, Àü·«Àû ±¸»ó ¹× ±â¼ú ¹ßÀüÀ¸·Î ÀÎÇØ ¿¹Ãø ±â°£ Áß »ó´çÇÑ ºÎ¹® ¼ºÀåÀÌ ¿¹»óµË´Ï´Ù.

Colonoscopy Devices-Market-IMG2

ºÏ¹Ì, ¿¹Ãø ±â°£ Áß Å« ÆøÀÇ ¼ºÀå ¿¹»ó

ºÏ¹Ì´Â ¿¹Ãø ±â°£ Áß »ó´çÇÑ ¼ºÀåÀ» º¸ÀÏ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ÀÌ·¯ÇÑ ¼ºÀåÀº ´ëÀå¾Ï ȯÀÚ Áõ°¡, Á¦Ç° Ãâ½Ã, Àü·«Àû ±¸»ó µîÀÇ ¿äÀο¡ ±âÀÎÇÕ´Ï´Ù. ¿¹¸¦ µé¾î ij³ª´Ù ¾Ï Çùȸ°¡ 2022³â 5¿ù¿¡ ¹ßÇ¥ÇÑ º¸°í¼­¿¡ µû¸£¸é 2022³â ³²¼º 13,500¸íÀÌ ´ëÀå¾Ï Áø´ÜÀ» ¹Þ°í 5,200¸íÀÌ »ç¸ÁÇÏ°í ¿©¼º 10,800¸íÀÌ ´ëÀå¾Ï Áø´ÜÀ» ¹Þ°í 4,200¸íÀÌ »ç¸ÁÇÒ °ÍÀ¸·Î ¿¹»óÇß½À´Ï´Ù. °°Àº ÀÚ·á¿¡ µû¸£¸é ¸ÅÀÏ Æò±Õ 67¸íÀÇ Ä³³ª´ÙÀÎÀÌ ´ëÀå¾Ï Áø´ÜÀ» ¹Þ°í ÀÖ´Ù°í ÇÕ´Ï´Ù. ¶ÇÇÑ ºÏ¹ÌÀÇ ´ëÀå ³»½Ã°æ °Ë»ç ºÐ¾ßÀÇ ¿¬±¸ ÀÛ¾÷ Áõ°¡µµ ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¿¹¸¦ µé¾î 2023³â 2¿ù ij³ª´Ù ¿¬±¸ÁøÀº ·¹ÀÌÀú ±â¹Ý Å©±â ÃøÁ¤ ±â´ÉÀ» °®Ãá »õ·Î¿î °¡»ó ½ºÄÉÀÏ ³»½Ã°æ(VSE)À» »ç¿ëÇÏ¿© ¶óÀÌºê ´ëÀå ³»½Ã°æ °Ë»ç Áß ´ëÀå ¿ëÁ¾ Å©±â¸¦ ÃøÁ¤ÇÏ´Â ÀÓ»ó ÆÄÀÏ·µ ¿¬±¸¸¦ ½ÃÀÛÇß½À´Ï´Ù. ÀÌó·³ ´ëÀå¾Ï ¹ßº´·ü Áõ°¡¿Í ÀÌ Áö¿ªÀÇ ¿¬±¸ Ȱµ¿ Áõ°¡·Î ÀÎÇØ »ó´çÇÑ ½ÃÀå ¼ºÀåÀÌ ¿¹»óµË´Ï´Ù.

¹Ì±¹¿¡¼­´Â ´ëÀå¾Ï ¹ßº´·üÀÌ Áõ°¡Çϰí ÀÖÀ¸¸ç, °í·É Àα¸ Áõ°¡°¡ ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇÏ´Â ÁÖ¿ä ¿äÀÎÀ¸·Î ÀÛ¿ëÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ Ä¡·áÀ² Áõ°¡, ¹Ì±¹³» ³ôÀº ´ëÀå¾Ï ¹ßº´·ü, ´Ù¸¥ ÁÖ¿ä Áö¿ª ´ëºñ ³ôÀº ¾à°¡µµ ½ÃÀå ¿ìÀ§ÀÇ ÁÖ¿ä ¿äÀÎÀ¸·Î ÀÛ¿ëÇϰí ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î ¹Ì±¹ ¾Ï ÇùȸÀÇ 2022³â ÃֽŠÁ¤º¸¿¡ µû¸£¸é ´ëÀå¾ÏÀº ¹Ì±¹¿¡¼­ 3¹øÂ°·Î ¸¹ÀÌ Áø´ÜµÇ´Â ¾ÏÀÔ´Ï´Ù. ¹Ì±¹¿¡¼­ »õ·Î Áø´ÜµÇ´Â ´ëÀå¾ÏÀº 106,180°Ç, Á÷Àå¾ÏÀº 44,850°ÇÀ¸·Î ÃßÁ¤µË´Ï´Ù. ¶ÇÇÑ ¾Ï ¹ßº´ÀÇ ÁÖ¿ä À§Çè ¿äÀÎ Áß Çϳª´Â ¿¬·ÉÀÔ´Ï´Ù. ¿¹¸¦ µé¾î 2022³â 5¿ù¿¡ ¾÷µ¥ÀÌÆ®µÈ ¹Ì±¹ÀÓ»óÁ¾¾çÇÐȸ ³í¹®¿¡ µû¸£¸é ´ëÀå¾ÏÀÇ ´ëºÎºÐÀº 50¼¼ À̻󿡼­ ¹ß»ýÇÑ´Ù°í º¸°íÇß½À´Ï´Ù. ´ëÀå¾Ï Áø´Ü½Ã Æò±Õ ¿¬·ÉÀº ³²¼º 68¼¼, ¿©¼º 72¼¼, Á÷Àå¾ÏÀÇ °æ¿ì ¹Ì±¹¿¡¼­´Â ³²³à ¸ðµÎ 63¼¼ÀÔ´Ï´Ù.

¶ÇÇÑ ¹Ì±¹¿¡¼­ÀÇ Á¦Ç° ½ÂÀÎ ¹× Ãâ½Ãµµ ¹Ì±¹ ½ÃÀåÀÇ ¼ºÀåÀ» °¡¼ÓÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¿¹¸¦ µé¾î 2022³â 4¿ù SMART Medical Systems Ltd´Â ¿Ã¸²Çª½º 510(k) ¼¼Ã´ Á¦Ç° PCF ½Ã¸®Áî ´ëÀå³»½Ã°æÀ» ±â¹ÝÀ¸·Î ÇÑ G-EYE ´ëÀå³»½Ã°æÀÇ FDA Çã°¡¸¦ ¹ßÇ¥Çß½À´Ï´Ù. À̹ø FDAÀÇ Ãß°¡ ½ÂÀÎÀ¸·Î G-EYE´Â ¹Ì±¹ ½ÃÀå¿¡ Ãâ½ÃµÉ ¿¹Á¤ÀÔ´Ï´Ù. ÀÌó·³ ´ëÀå¾ÏÀÇ ³ôÀº ¹ßº´·üÀº ±× Áø´Ü°ú Ä¡·á¸¦ ÃËÁøÇÏ¿© Á¶»çµÈ ½ÃÀåÀ» ÁÖµµÇϰí ÀÖ½À´Ï´Ù.

´ëÀå³»½Ã°æ °Ë»ç ±â±â »ê¾÷ °³¿ä

´ëÀå³»½Ã°æ °Ë»ç ±â±â ½ÃÀåÀº °æÀïÀÌ Ä¡¿­ÇÏ°í ¿©·¯ ¼¼°è ±â¾÷À¸·Î ±¸¼ºµÇ¾î ÀÖ½À´Ï´Ù. ½ÃÀåÀÌ ¹ßÀüÇÔ¿¡ µû¶ó °¢ ±â¾÷Àº ¿ëµµ¿¡ µû¶ó ´ëÀå³»½Ã°æ ½Ã½ºÅÛÀÇ ¸íÈ®ÇÑ Â÷º°È­¸¦ ²ÒÇϰí ÀÖ½À´Ï´Ù. °íÈ­Áú ¿µ»ó°ú ¼ö¼ú ´É·Â¿¡ ´ëÇÑ ¿ä±¸·Î ÀÎÇØ ´Ù¾çÇÑ °í°´ ±×·ìÀÌ ´ëÀå³»½Ã°æ°ú Ä«¸Þ¶ó°¡ ÅëÇÕµÈ ÃÖÀûÈ­µÈ ½Ã°¢È­ ½Ã½ºÅÛÀ¸·Î À̵¿Çϰí ÀÖ½À´Ï´Ù. ÇöÀç ½ÃÀå¿¡ ÁøÃâÇÑ ±â¾÷À¸·Î´Â Boston Scientific Corporation, Fujifilm Corporation, Olympus Corporation, PENTAX Medical, Medtronic. µîÀÌ ÀÖ½À´Ï´Ù.

±âŸ ƯÀü

  • ¿¢¼¿ Çü½ÄÀÇ ½ÃÀå ¿¹Ãø(ME) ½ÃÆ®
  • 3°³¿ù°£ÀÇ ¾Ö³Î¸®½ºÆ® Áö¿ø

¸ñÂ÷

Á¦1Àå ¼­·Ð

  • Á¶»çÀÇ ÀüÁ¦Á¶°Ç°ú ½ÃÀå Á¤ÀÇ
  • Á¶»ç ¹üÀ§

Á¦2Àå Á¶»ç ¹æ¹ý

Á¦3Àå ÁÖ¿ä ¿ä¾à

Á¦4Àå ½ÃÀå ¿ªÇÐ

  • ½ÃÀå °³¿ä
  • ½ÃÀå ÃËÁø¿äÀÎ
    • ´ëÀå¾ÏÀÇ Áõ°¡
    • ´ëÀå³»½Ã°æ ±â±âÀÇ ±â¼ú Áøº¸
  • ½ÃÀå ¾ïÁ¦¿äÀÎ
    • Á÷Àå ÁúȯÀÇ ´ëü Ä¡·áÀÇ ÀÌ¿ë °¡´É¼º
    • ´ëÀå³»½Ã°æ °Ë»ç¿¡ ¼ö¹ÝÇÏ´Â ¸®½ºÅ©
  • Porter's Five Forces ºÐ¼®
    • ±¸¸ÅÀÚ/¼ÒºñÀÚÀÇ ±³¼··Â
    • °ø±Þ ±â¾÷ÀÇ ±³¼··Â
    • ½Å±Ô ÁøÃâ¾÷üÀÇ À§Çù
    • ´ëüǰÀÇ À§Çù
    • °æÀï ±â¾÷°£ °æÀï °­µµ

Á¦5Àå ½ÃÀå ¼¼ºÐÈ­(½ÃÀå ±Ô¸ð, ±Ý¾× ±â¹Ý)

  • Á¦Ç° À¯Çüº°
    • ´ëÀå³»½Ã°æ
    • °¡½ÃÈ­ ½Ã½ºÅÛ
    • ±âŸ Á¦Ç° À¯Çü
  • ¿ëµµº°
    • ´ëÀå¾Ï
    • ¸°Ä¡ ÁõÈıº
    • ±Ë¾ç¼º ´ëÀå¿°
    • Å©·Ðº´
    • ±âŸ ¿ëµµ
  • ÃÖÁ¾»ç¿ëÀÚº°
    • º´¿ø
    • ¿Ü·¡ ¼ö¼ú ¼¾ÅÍ
    • ±âŸ ÃÖÁ¾»ç¿ëÀÚ
  • Áö¿ªº°
    • ºÏ¹Ì
      • ¹Ì±¹
      • ij³ª´Ù
      • ¸ß½ÃÄÚ
    • À¯·´
      • µ¶ÀÏ
      • ¿µ±¹
      • ÇÁ¶û½º
      • ÀÌÅ»¸®¾Æ
      • ½ºÆäÀÎ
      • ±âŸ À¯·´
    • ¾Æ½Ã¾ÆÅÂÆò¾ç
      • Áß±¹
      • ÀϺ»
      • Àεµ
      • È£ÁÖ
      • Çѱ¹
      • ±âŸ ¾Æ½Ã¾ÆÅÂÆò¾ç
    • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
      • GCC
      • ³²¾ÆÇÁ¸®Ä«°øÈ­±¹
      • ±âŸ Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
    • ³²¹Ì
      • ºê¶óÁú
      • ¾Æ¸£ÇîÆ¼³ª
      • ±âŸ ³²¹Ì

Á¦6Àå °æÀï ±¸µµ

  • ±â¾÷ °³¿ä
    • Boston Scientific Corporation
    • Fujifilm Corporation
    • Olympus Corporation
    • PENTAX Medical
    • Karl Storz SE & Co. KG
    • Medtronic
    • Steris PLC
    • Hoya Corporation
    • Endomed Systems
    • Getinge AB
    • Avantis Medical Systems

Á¦7Àå ½ÃÀå ±âȸ ¹× ÇâÈÄ Àü¸Á

KSA 24.01.19
Colonoscopy Devices - Market - IMG1

The global colonoscopy devices market is valued at USD 2.24 billion in 2024 and is expected to reach USD 2.88 billion by 2029 with a CAGR of 5.20% over the forecast period (2024-2029).

The pandemic imposed an adverse impact on the market during the initial days. The suspension or delay of colorectal cancer treatment during the pandemic posed a slight adverse impact on the market to some extent in the initial days. For instance, according to the article published by Health Canada published in June 2021, colorectal cancer screening, along with other healthcare services, was suspended in Canada in the initial phase of the COVID-19 pandemic response. This pause was necessary to allow healthcare facilities to establish appropriate infection-control measures to prevent COVID-19 outbreaks and reserve health system capacity for COVID-19 patients. However, in the later times of the pandemic, several awareness programs related to cancer screening and, with the resumption of screening services, the market gradually started to gain traction. For instance, a notable example is the Community Oncology Alliance (COA) and Cancer Care collaboration in April 2021 to launch a new public awareness campaign dubbed "Time to Screen." The campaign was aimed at increasing focus on cancer screening by publishing educational information regarding screening for various types of cancer and assistance for screening appointments. Thus, initially, the market witnessed an adverse impact; however, with the resumption of cancer treatment, the market started to gain traction and is expected to maintain an upward trend over the forecast period.

The colonoscopy device market is driven by the increasing preference for minimally invasive techniques, technological advancements, and the rising prevalence of colorectal cancer. The causes of colorectal cancer are unspecified. Moreover, several genetic and environmental factors may increase the risk of developing the disease. For instance, according to the research article published by the American Cancer Society in March 2023, around 1,53,020 individuals are expected to be diagnosed with colorectal cancer. Around 52,550 individuals in the United States are expected to die from colorectal cancer in 2023. In addition, the same source also stated that around 106,970 new cases of colon cancer and 46,050 new cases of rectal cancer are expected to occur in the United States in 2023. Moreover, factors such as upcoming launches of promising pipeline candidates, the emergence of more front-line therapies, and favorable government initiatives are likely to fuel market expansion.

Furthermore, adopting various strategies in the studied market is also expected to boost market growth. For instance, in July 2022, US Digestive Health ('USDH'), a network of top-rated gastrointestinal (GI) practices, announced that it offered patients AI-assisted colonoscopy screenings with the country's largest installation of GI Genius intelligent endoscopy modules. Colonoscopy has long been considered the gold standard for detecting polyps that can eventually lead to colorectal cancer. Now, patients at USDH have the strength of an AI-assisted option for screening with GI Genius, the Food and Drug Administration (FDA) cleared device that employs AI to help physicians detect polyps. Furthermore, in August 2022, India Medtronic Pvt Limited launched India's GI Genius intelligent endoscopy module. The GI Genius module uses advanced AI software to highlight suspicious polyps of various sizes, shapes, and morphologies with a real-time visual marker. It serves gastroenterologists as an ever-vigilant second observer with a lesion sensitivity rate of 99.7% and less than 1% false-positive results. Thus, product launches and technological advancements are expected to propel the market growth over the forecast period.

However, the availability of alternative treatments for rectal disease and the risk associated with colonoscopy procedures may hamper the market growth over the forecast period.

Colonoscopy Devices Market Trends

Colonoscope Segment is Expected to Witness Considerable Growth Over the Forecast Period

Colonoscopy devices detect lesions in the proximal aspect of colonic folds either by offering a retrograde view of the lumen or straightening the haustral folds during withdrawal. It improves quality indicators and other metrics associated with the examination's outcomes. Associated advantages of colonoscopy over other treatment alternatives, such as improved precision, accuracy, and treatment safety, are anticipated to increase its demand in surgical centers.

The alarming rise of colorectal cancer is also expected to boost the demand for colonoscopy devices over the forecast period. For instance, according to the NCBI study published in July 2021, more than 5.25 million people globally were living with colorectal cancer. The global number of new colorectal cancer cases is predicted to reach 3.2 million in 2040. Thus, such instances indicate that annual colonoscopy procedures are also likely to grow, thereby boosting segment growth. Furthermore, several companies are adopting various strategies to grow their presence in the market. For instance, In April 2021, FUJIFILM launched the G-EYE 700 Series Colonoscope. G-EYE is a technology developed by Smart Medical to assist with visualization, stabilization, and control during routine examinations.

Similarly, in November 2021, Cosmo Pharmaceuticals N.V. announced topline results from a randomized, international, multi-center study evaluating the safety and efficacy of the artificial intelligence (A.I.) device G.I. Genius as an aid for the detection of colorectal polyps in combination with colonoscopy. This study provides a wide experience of using the device in clinical settings, and the results show how effective G.I. Genius is in reducing the percentage of adenomas and polyps that go undetected during white light colonoscopy. In addition, companies are also efforts to incorporate advanced technologies in the existing product lines, which may also drive segment growth. For instance, in December 2022, Bharti Airtel and Apollo Hospitals announced that they had conducted India's first artificial intelligence (A.I.) controlled 5G colonoscopy trial. In this study, Airtel's 5G technology was used to detect colon cancer faster and more accurately with A.I. applications. This technology has ultra-low latency and high processing capabilities. Thus, considerable segment growth is expected over the forecast period due to the rising burden of colorectal cancer, product launches, strategic initiatives, and technological advancements.

Colonoscopy Devices - Market - IMG2

North America is Expected Witness Significant Growth Over the Forecast Period

North America is expected to witness considerable growth over the forecast period. The growth is due to factors such as the rising cases of colorectal cancer, product launches, and strategic initiatives. For instance, according to the report published by the Canadian Cancer Society in May 2022, 13,500 men were diagnosed with colorectal cancer, 5,200 died from it, 10,800 women were diagnosed with colorectal cancer, and 4,200 died in 2022. The same source also stated that, on average, 67 Canadians were diagnosed with colorectal cancer daily. Furthermore, increasing research work in the colonoscopy space in the North American region is also expected to propel market growth. For instance, in February 2023, researchers in Canada launched a clinical pilot study to measure colorectal polyp size during live colonoscopies using a new virtual scale endoscope (VSE) with a laser-based size measurement function. Thus, considerable market growth is expected to be seen owing to the rising burden of colorectal cancer and increasing research work in the region.

The increasing burden of colorectal cancer and the rising geriatric population in the United States are the major factors propelling the market growth in the country. Other key factors responsible for its dominance are increased treatment rates, a high incidence of colorectal cancer in the country, and inflated medicine prices compared to other major regions. For instance, per the American Cancer Society 2022 updates, colorectal cancer is the third most common cancer diagnosed in the United States. There will be an estimated 106,180 new colon cancer and 44,850 cases of rectal cancer diagnosed in the United States. Furthermore, one of the major risk factors for developing cancer is age. For instance, the American Society of Clinical Oncology article updated in May 2022 reported that most colorectal cancers occur in people older than 50. The average age at the time of diagnosis for colon cancer in men is 68 years, and that for women is 72 years, while for rectal cancer, it is age 63 years for both men and women in the United States.

Furthermore, product approvals and launches in the United States are also expected to propel the market growth in the United States. For instance, in April 2022, SMART Medical Systems Ltd announced its FDA clearance for its G-EYE colonoscope, based on the PCF series of colonoscopes with Olympus 510(k) cleaned products. With this additional FDA clearance, G-EYE is now available in the United States market. Thus, the high incidence of colorectal cancer will drive its diagnosis and treatment, driving the studied market.

Colonoscopy Devices Industry Overview

The colonoscopy devices market is highly competitive and consists of several global players. As the market progresses, the firms try to achieve clear differentiation in colonoscopy systems based on their application. Due to the requirements for high-quality imaging and operative capabilities, various customer groups are shifting toward optimized visualization systems that integrate colonoscopes and cameras. Some companies currently in the market are Boston Scientific Corporation, Fujifilm Corporation, Olympus Corporation, PENTAX Medical, and Medtronic.

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 Study Assumptions and Market Definition
  • 1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Increasing Number of Colorectal Cancer
    • 4.2.2 Technological Advancements In Colonoscope Devices
  • 4.3 Market Restraints
    • 4.3.1 Availability of Alternative Treatment for Rectal Disease
    • 4.3.2 Risk Associated with Colonoscopy Procedures
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Bargaining Power of Buyers/Consumers
    • 4.4.2 Bargaining Power of Suppliers
    • 4.4.3 Threat of New Entrants
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION (Market Size by Value - USD)

  • 5.1 By Product Type
    • 5.1.1 Colonoscope
    • 5.1.2 Visualization Systems
    • 5.1.3 Other Product Types
  • 5.2 By Applications
    • 5.2.1 Colorectal Cancer
    • 5.2.2 Lynch Syndrome
    • 5.2.3 Ulcerative Colitis
    • 5.2.4 Crohn's Disease
    • 5.2.5 Other Applications
  • 5.3 By End-User
    • 5.3.1 Hospitals
    • 5.3.2 Ambulatory Surgery Center
    • 5.3.3 Other End-Users
  • 5.4 Geography
    • 5.4.1 North America
      • 5.4.1.1 United States
      • 5.4.1.2 Canada
      • 5.4.1.3 Mexico
    • 5.4.2 Europe
      • 5.4.2.1 Germany
      • 5.4.2.2 United Kingdom
      • 5.4.2.3 France
      • 5.4.2.4 Italy
      • 5.4.2.5 Spain
      • 5.4.2.6 Rest of Europe
    • 5.4.3 Asia-Pacific
      • 5.4.3.1 China
      • 5.4.3.2 Japan
      • 5.4.3.3 India
      • 5.4.3.4 Australia
      • 5.4.3.5 South Korea
      • 5.4.3.6 Rest of Asia-Pacific
    • 5.4.4 Middle-East and Africa
      • 5.4.4.1 GCC
      • 5.4.4.2 South Africa
      • 5.4.4.3 Rest of Middle-East and Africa
    • 5.4.5 South America
      • 5.4.5.1 Brazil
      • 5.4.5.2 Argentina
      • 5.4.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Boston Scientific Corporation
    • 6.1.2 Fujifilm Corporation
    • 6.1.3 Olympus Corporation
    • 6.1.4 PENTAX Medical
    • 6.1.5 Karl Storz SE & Co. KG
    • 6.1.6 Medtronic
    • 6.1.7 Steris PLC
    • 6.1.8 Hoya Corporation
    • 6.1.9 Endomed Systems
    • 6.1.10 Getinge AB
    • 6.1.11 Avantis Medical Systems

7 MARKET OPPORTUNITIES AND FUTURE TRENDS

»ùÇà ¿äû ¸ñ·Ï
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦